1. Which statement regarding hypothyroidism in dogs is correct?
A. Dogs are much more likely to suffer hyperthyroidism than hypothyroidism.
B. Levothyroxine is administered orally twice daily in dogs.
C. Levothyroxine is not approved for use in dogs.
D. Pharmacists may legally substitute equal dosages of Synthroid® for prescriptions written for levothyroxine in dogs without consulting the veterinarian.
2. Which of the following statements regarding treatment of canine hyperadrenocorticism is correct?
A. The most common presentation of hyperadrenocorticism in dogs is adrenal-dependent disease.
B. Trilostane is FDA-approved for use in dogs and is the drug of choice for treating canine hyperadrenocorticism.
C. Mitotane approved for humans is used off-label to treat canine hyperadrenocorticism and is the drug of choice.
D. Ketoconazole is considered to be as effective as trilostane or mitotane for the treatment of canine hyperadrenocorticism.
3. Water consumption for a 32-kg dog being treated for hyperadrenocorticism should drop below how many milliliters per day to indicate that the dog is responding to trilostane or mitotane therapy:
A. 2.5 liters
B. 2 liters
C. 1.5 liters
D. 1 liter
4. Which of the following drugs is prescribed as an alternative to desoxycorticosterone pivalate (DCOP) for the treatment of hypoadrenocorticism in dogs?
A. Fluticasone
B. Mitotane
C. Fludrocortisone
D. Trilostane
5. Which of the following insulins is FDA-approved for use in dogs with diabetes?
A. Insulin detemir
B. Insulin glargine
C. NPH insulin suspension
D. Porcine insulin zinc suspension
6. Chloride intake must be strictly regulated in dogs receiving which of the following drugs for epilepsy?
A. Levetiracetam
B. Phenobarbital
C. Potassium bromide
D. Zonisamide
7. Choose the CORRECT statement regarding drug therapy for canine epilepsy:
A. Neurontin® (gabapentin) Oral Solution is commonly used to treat small dogs with epilepsy.
B. Felbamate blood levels are monitored closely in dogs to ensure that concentrations are in the established therapeutic range.
C. Pharmacists may pre-draw doses of diazepam injection into syringes for owners of epileptic dogs to administer rectally in the event of status epilepticus.
D. Potassium bromide should not be given with salty foods because excess chloride can lower the seizure threshold.
8. Which of the following pairings of drug and patient does not reflect appropriate therapy for canine urinary incontinence?
A. Diesthylstilbestrol for a male dog with urinary incontinence
B. Estriol for a female dog with urinary incontinence
C. Phenylpropanolamine for a female dog with urinary incontinence
D. Phenylpropanolamine for a male dog with urinary incontinence
9. According to the American College of Veterinary Internal Medicine consensus classification of heart disease and heart failure, a dog with heart enlargement and symptoms of congestive heart failure is in:
A. Stage A.
B. Stage B2.
C. Stage C.
D. Stage D.
10. Which of the following statements about drug therapy for canine chronic valvular heart disease is correct?
A. Digoxin is the drug of choice for treating congestive heart failure in dogs.
B. Hydrocodone bitartrate is FDA-approved for use as an antitussive in dogs.
C. Pimobendan is a positive inotrope that is FDA-approved for use in dogs but not in humans.
D. Spironolactone approved for humans may be used off-label for diuresis in dogs.
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Will the information presented cause you to change your practice?
A. Yes
B. No
22. Are you committed to making these changes?
A. Yes
B. No
23. As a result of this activity, did you learn something new?
A. Yes
B. No
24. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
25. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20